| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-adrenoreceptor antagonists | 520 | 51781-06-7 |
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 60 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.49 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 88 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| CL (Clearance) | 10.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.70 hours | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 10.13 mL/min/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| Vd (Volume of distribution) | 4.05 L/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 28, 1988 | FDA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Intraocular pressure increased | 67.85 | 34.07 | 14 | 417 | 6064 | 63482527 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatitis fulminant | 46.93 | 39.77 | 10 | 277 | 4180 | 34952464 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Intraocular pressure increased | 67.32 | 30.38 | 16 | 755 | 9189 | 79734428 |
| Choluria | 30.77 | 30.38 | 5 | 766 | 401 | 79743216 |
| Bradycardia | 30.65 | 30.38 | 18 | 753 | 135539 | 79608078 |
None
| Source | Code | Description |
|---|---|---|
| ATC | C07AA15 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, non-selective |
| ATC | S01ED05 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
| ATC | S01ED55 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
| FDA MoA | N0000000161 | Adrenergic beta-Antagonists |
| FDA EPC | N0000175556 | beta-Adrenergic Blocker |
| CHEBI has role | CHEBI:35530 | beta-adrenergic blockers |
| CHEBI has role | CHEBI:35674 | antihypertensive drugs |
| CHEBI has role | CHEBI:38070 | antiarrhythmic agent |
| CHEBI has role | CHEBI:39456 | antiglaucoma agent |
| CHEBI has role | CHEBI:66991 | sympatholytic drug |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D000319 | Adrenergic beta-Antagonists |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D013565 | Sympatholytics |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ocular hypertension | indication | 4210003 | DOID:9282 |
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
| Angina pectoris | off-label use | 194828000 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Anaphylaxis | contraindication | 39579001 | |
| Sinus bradycardia | contraindication | 49710005 | |
| Chronic bronchitis | contraindication | 63480004 | DOID:6132 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Pulmonary emphysema | contraindication | 87433001 | |
| Cardiogenic shock | contraindication | 89138009 | |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Second degree atrioventricular block | contraindication | 195042002 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Pregnancy, function | contraindication | 289908002 | |
| Severe chronic obstructive pulmonary disease | contraindication | 313299006 |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.31 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Ki | 9.30 | WOMBAT-PK | CHEMBL | |||
| Beta-2 adrenergic receptor | GPCR | ANTAGONIST | Ki | 9.20 | WOMBAT-PK | CHEMBL |
| ID | Source |
|---|---|
| 4019351 | VUID |
| N0000147523 | NUI |
| D00599 | KEGG_DRUG |
| 51781-21-6 | SECONDARY_CAS_RN |
| 142132 | RXNORM |
| C0007299 | UMLSCUI |
| CHEBI:3437 | CHEBI |
| CHEMBL839 | ChEMBL_ID |
| DB00521 | DRUGBANK_ID |
| CHEMBL1201002 | ChEMBL_ID |
| D002354 | MESH_DESCRIPTOR_UI |
| 2583 | PUBCHEM_CID |
| 7142 | IUPHAR_LIGAND_ID |
| 3990 | INN_ID |
| 8NF31401XG | UNII |
| 31453 | MMSL |
| 4361 | MMSL |
| 4362 | MMSL |
| d00708 | MMSL |
| 108544005 | SNOMEDCT_US |
| 386866004 | SNOMEDCT_US |
| 386867008 | SNOMEDCT_US |
| 4019351 | VANDF |
| 4020617 | VANDF |
| 001863 | NDDF |
| 004747 | NDDF |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Carteolol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61314-238 | SOLUTION | 10 mg | OPHTHALMIC | ANDA | 19 sections |